News

HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world’s first malaria vaccine – RTS,S or Mosquirix – by over half to ...
Bharat Biotech and GSK announce price reduction for the world's first malaria vaccine to under $5. This move aims to improve access and save thousands of children in malaria-endemic countries.
Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world's first malaria vaccine for children 'RTS,S' developed by GSK, PATH and partners, by more than ...
As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial design and fundraising, framed the deal as a way to get the vaccine to ...
The GSK-Bharat Biotech partnership includes support for the design of the Phase III trial and assistance in securing external funding. The partnership strengthens GSK’s current relationship with ...
In a recent development, Bharat Biotech and GSK announced a price reduction of $5, which aims to improve access and save thousands of children who suffer from malaria.
GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...
GSK and Bharat Biotech Deepen Global Health Collaboration. As part of the agreement, GSK will support Phase III trial design and help Bharat Biotech pursue external funding. The move builds on a ...
The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates ...